 MARLBOROUGH, Mass., June 14, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn, will participate in the AGP Summer Healthcare Symposium and a fireside chat hosted by H.C. 